Ocrevus After One Year On The Market What Do We Know Now
Ocrevus is groundbreaking because, while it has been very effective for RRMS, it is also the first medication approved to treat primary-progressive multiple sclerosis (PPMS), a less-common form of the disease. According to the National Multiple Sclerosis Society, 85 percent of people with MS have RRMS, while 10 to 15 percent are diagnosed with PPMS. Before Ocrevus, there was very little doctors could do for their patients with PPMS other than provide medications and other therapies to treat the symptoms....